Jyong Biotech Ltd. (JYB)

Jyong Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021
Cash & Equivalents	1.74	2.27	0.55
Short-Term Investments	-	0.09	1.83
Cash & Cash Equivalents	1.74	2.37	2.39
Cash Growth	-26.44%	-0.71%	-
Other Current Assets	0.1	0.1	0.26
Total Current Assets	1.84	2.46	2.65
Property, Plant & Equipment	3.39	3.51	3.77
Goodwill and Intangibles	0.16	2.49	3.01
Other Long-Term Assets	2.87	0.28	0.01
Total Long-Term Assets	6.41	6.28	6.78
Total Assets	8.25	8.75	9.43
Accounts Payable	0	0	0.05
Current Debt	8.16	7.82	5.18
Other Current Liabilities	6.1	5.09	1.07
Total Current Liabilities	14.26	12.91	6.29
Long-Term Debt	8.59	6.43	6.61
Other Long-Term Liabilities	19.47	19.04	19.86
Total Long-Term Liabilities	28.06	25.47	26.46
Total Liabilities	42.32	38.38	32.76
Total Debt	16.75	14.25	11.79
Debt Growth	17.51%	20.88%	-
Retained Earnings	-30.06	-25.66	-19.03
Comprehensive Income	0.55	0.59	0.27
Shareholders' Equity	-34.07	-29.63	-23.33
Net Cash / Debt	-15	-11.88	-9.4
Working Capital	-12.42	-10.44	-3.65

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).